Agenus to Host End-of-Year Stakeholder Webcast Featuring GI Oncology Leaders and Progress of BOT/BALBusiness Wire • 11/19/25
Agenus Appoints Dr. José Iglesias as Chief Medical Affairs Officer to Guide Global Medical Affairs and Early-Access Programs, Including France's AACBusiness Wire • 11/18/25
Agenus Reports 39% of Patients Alive at Two-Years with BOT/BAL Across Multiple Refractory Solid Tumors at ESMO 2025Business Wire • 10/17/25
Agenus to Host October Stakeholder Briefing Showcasing BOT/BAL Global Momentum and Post-ESMO InsightsBusiness Wire • 10/16/25
France Grants Reimbursed Compassionate Access (AAC) for Agenus' BOT/BAL in Refractory MSS Metastatic Colorectal CancerBusiness Wire • 09/09/25
Agenus to Participate in the H.C. Wainwright 27th Annual Global Investment ConferenceBusiness Wire • 09/05/25
Update: Agenus Aug 27 Stakeholder Webcast—Transformative IO Updates, BOT/BAL Data, BATTMAN Preview, Zydus Partnership Momentum, and MiNK SpotlightBusiness Wire • 08/26/25
Agenus to Unveil BOT/BAL Strategic Advancements, Key Milestones, and Future Outlook in Virtual Stakeholder Briefing on August 27, 2025Business Wire • 08/19/25
Agenus Announces Second Quarter 2025 Financial Results and Virtual Meeting to Discuss Strategic ProgressBusiness Wire • 08/11/25
Agenus to Highlight Emerging Survival Plateaus with Botensilimab/Balstilimab in Oral Presentation of Study in Refractory Patients Across Five Tumor Types at ESMO 2025Business Wire • 07/25/25
Agenus (AGEN) Surges 19.3%: Is This an Indication of Further Gains?Zacks Investment Research • 07/14/25
Agenus' BOT/BAL Achieves 42% Two-Year Survival in Refractory MSS CRC, Advances Toward Registration with FDA Alignment on Phase 3Business Wire • 07/07/25
Agenus and Noetik Enter Collaboration to Develop AI-Enabled Predictive Biomarkers for BOT/BAL Using Foundation Models of Virtual Cell BiologyBusiness Wire • 06/17/25
Wall Street Analysts Believe Agenus (AGEN) Could Rally 26.6%: Here's is How to TradeZacks Investment Research • 06/04/25